ConductScience.org, home

Trial · NCT02684786

Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryNumber of participants with treatment-related adverse events as assessed by CTCAE v4.0one month
Adverse events of interest are for stellate ganglion block: pulmonary edema, bradycardia requiring treatment, hypotension requiring treatment, arrhythmia, pneumothorax, hoarseness, dysphagia, globus, left upper extremity weakness. For reserpine, heart failure hospitalization, syncope, all cause hospitalization, bradycardia requiring treatment, hypotension requiring treatment, new arrhythmia, edema requiring an increase in diuretics, depression, lethargy, nasal stuffiness, dizziness, orthostatic hypotension, falls, nightmares, sexual dysfunction, anxiety, dyspepsia. Adverse events classed as serious: * Life threatening serious adverse events including acute coronary syndrome with active ischemia, fatal arrhythmias, myocardial infarction, acute kidney injury, cardiogenic shock, stroke, pulmonary embolization, arterial and/or venous thrombosis, systemic embolization, severe hypotension, respiratory failure and death * Prolonged hospitalization or rehospitalization
SecondaryNumber of participants with successful stellate ganglion blockOne hourStellate block: frequency of the occurrence of ptosis and conjunctival flushing.
SecondaryEffect of stellate ganglion block on heart rateOne hourHeart rate before and after stellate ganglion block
SecondaryChange in 6 minute walk distance from one month of reserpine therapyOne monthSix minute walk distance, meters, baseline compared to one month
SecondaryChange in brain natriuretic peptide (BNP) from one month of reserpine therapyOne monthBNP, pg/ml, baseline compared to one month
SecondaryChange in Doppler derived mean pulmonary artery pressure from one month of reserpine therapyOne monthMean pulmonary artery pressure estimate, mm Hg
SecondaryChange in blood pressure from one month of reserpine therapyOne monthBlood pressure, mm Hg, baseline versus one month
SecondaryChange in Minnesota Living with heart failure questionnaire from one month of reserpine therapyOne monthMinnesota Living with heart failure questionnaire aggregate score, baseline versus one month
SecondaryHemodynamic effect of stellate ganglion blockOne hourBlood pressure, mm Hg, before and after stellate ganglion block
SecondaryHemodynamic effect of stellate ganglion blockOne hourPulmonary artery pressure, mm Hg, before and after stellate ganglion block
SecondaryHemodynamic effect of stellate ganglion blockOne hourPulmonary capillary wedge pressure, mm Hg, before and after stellate ganglion block
SecondaryHemodynamic effect of stellate ganglion blockOne hourright atrial pressure, mm Hg, before and after stellate ganglion block
SecondaryHemodynamic effect of stellate ganglion blockOne hourCardiac output, liters per minute, before and after stellate ganglion block
SecondaryChange in heart rate from one month of reserpine therapyOne monthHeart rate, baseline versus one month

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02684786/registered